Nordazepam

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Nordazepam
Accession Number
DB14028
Type
Small Molecule
Groups
Experimental
Description

An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.

Structure
Thumb
Synonyms
  • Desmethyldiazepam
  • N-desmethyldiazepam
  • Nordazepam CIV
  • Nordazepamum
  • Nordiazepam
External IDs
A 101 / A101 / RO 5-2180
International/Other Brands
Calmday / Lomax / Madar / Sopax / Stilny / Vegesan
Categories
UNII
67220MCM01
CAS number
1088-11-5
Weight
Average: 270.714
Monoisotopic: 270.055990691
Chemical Formula
C15H11ClN2O
InChI Key
AKPLHCDWDRPJGD-UHFFFAOYSA-N
InChI
InChI=1S/C15H11ClN2O/c16-11-6-7-13-12(8-11)15(17-9-14(19)18-13)10-4-2-1-3-5-10/h1-8H,9H2,(H,18,19)
IUPAC Name
7-chloro-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-2-one
SMILES
ClC1=CC=C2NC(=O)CN=C(C3=CC=CC=C3)C2=C1

Pharmacology

Indication
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteraction
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of adverse effects can be increased when 2,5-Dimethoxy-4-ethylthioamphetamine is combined with Nordazepam.
3-isobutyl-1-methyl-7H-xanthineThe therapeutic efficacy of Nordazepam can be decreased when used in combination with 3-isobutyl-1-methyl-7H-xanthine.
3,4-MethylenedioxyamphetamineThe risk or severity of adverse effects can be increased when 3,4-Methylenedioxyamphetamine is combined with Nordazepam.
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Nordazepam.
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when 4-Methoxyamphetamine is combined with Nordazepam.
5-methoxy-N,N-dimethyltryptamineThe risk or severity of adverse effects can be increased when 5-methoxy-N,N-dimethyltryptamine is combined with Nordazepam.
6-O-benzylguanineThe therapeutic efficacy of Nordazepam can be decreased when used in combination with 6-O-benzylguanine.
7-DeazaguanineThe therapeutic efficacy of Nordazepam can be decreased when used in combination with 7-Deazaguanine.
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Nordazepam.
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of adverse effects can be increased when 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline is combined with Nordazepam.
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0060538
KEGG Drug
D08283
KEGG Compound
C07486
ChemSpider
2890
BindingDB
50027835
ChEBI
111762
ChEMBL
CHEMBL523
Wikipedia
Nordazepam
ATC Codes
N05BA16 — Nordazepam

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0219 mg/mLALOGPS
logP2.79ALOGPS
logP3.21ChemAxon
logS-4.1ALOGPS
pKa (Strongest Acidic)12.3ChemAxon
pKa (Strongest Basic)2.85ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.46 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity76.7 m3·mol-1ChemAxon
Polarizability27.41 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-006x-1290000000-16289dee622e983dadb4
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-014i-0090000000-08ab493d917dff556803
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-b3902adae33dd2ada996
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-e1f36555cb45aafb3578
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-4599707b6c514e2fd140
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0006-0090000000-2afa9f8bad136457e913
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-052f-0090000000-39292916fbbd987c9c79
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0490000000-93d06070b3ddb4f2bb1d
LC-MS/MS Spectrum - LC-ESI-QFT , negativeLC-MS/MSsplash10-0udi-0900000000-319db7de66dd214c6036
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00di-0090000000-f12d8a37190a6a1a6260
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00dl-0590000000-6667f22f2eaaa4d7d444
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-05mo-0950000000-9f91849bf0ea300eddf6
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-052f-0940000000-113f94a665f60922a3cc
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0090000000-a17b063554f54d5ae790
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0090000000-00d132ae0ea246d26e2a
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-00di-0390000000-02873020d1329d3d5c38
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-1960000000-010c3ba06f80d4ace994
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-052f-1930000000-327cc931b60592065b64
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0006-2910000000-0a0897ca546d1bc1cb27
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0f6x-4900000000-7cc6b852b0d715a021c2
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0ufr-7900000000-d4ef23e43b78528b7c96
LC-MS/MS Spectrum - LC-ESI-QFT , positiveLC-MS/MSsplash10-0w4i-9700000000-9ef8e88327da379c2b33

Taxonomy

Description
This compound belongs to the class of organic compounds known as 1,4-benzodiazepines. These are organic compounds containing a benzene ring fused to a 1,4-azepine.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Benzodiazepines
Sub Class
1,4-benzodiazepines
Direct Parent
1,4-benzodiazepines
Alternative Parents
Benzene and substituted derivatives / Aryl chlorides / Cyclic carboximidic acids / Ketimines / Propargyl-type 1,3-dipolar organic compounds / Azacyclic compounds / Organopnictogen compounds / Organooxygen compounds / Organochlorides / Hydrocarbon derivatives
Substituents
1,4-benzodiazepine / Aryl chloride / Aryl halide / Monocyclic benzene moiety / Benzenoid / Cyclic carboximidic acid / Ketimine / Organic 1,3-dipolar compound / Propargyl-type 1,3-dipolar organic compound / Azacycle
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
organochlorine compound, 1,4-benzodiazepinone (CHEBI:111762)

Drug created on May 15, 2018 14:27 / Updated on November 02, 2018 07:49